(Q38138849)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Signaling between tumor cells and the host bone marrow microenvironment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Michelle M McDonald

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Natasa Kovacic

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

18 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

Calcified Tissue International

22 February 2020

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

125-139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24046000%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00223-013-9794-7

22 February 2020

exact match

0 references

cites work

Clinical features of metastatic bone disease and risk of skeletal morbidity

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Dormancy of solitary metastatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Involvement of chemokine receptors in breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

CYP2C and IL-6 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Metastatic breast cancer induces an osteoblast inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Integrins and signaling in osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Bone morphogenetic protein-6 expression in normal and malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

BMP4 promotes prostate tumor growth in bone through osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Role of Wnts in prostate cancer bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Osteoclasts are active in bone forming metastases of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Myeloma cells suppress osteoblasts through sclerostin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Sclerostin: a possible target for the management of cancer-induced bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Endothelin antagonists in hypertension and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Rho-kinase regulates endothelin-1-stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Cooperative effects in differentiation and proliferation between PDGF-BB and matrix derived synthetic peptides in human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-013-9794-7